Drug intelligence / Profile preview

SC-51296

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

SC-51296 is a **small molecule antagonist** of the **serotonin 5-HT3 receptor**. It has been studied primarily for its potential effects on ethanol self-administration, with research indicating that it does not significantly alter ethanol intake in preclinical models. SC-51296 acts by blocking the serotonin 5-HT3 receptor, a ligand-gated ion channel implicated in various neuropsychiatric and gastrointestinal processes. There is limited information about its clinical development, and it has not advanced to approval for any major indication.

Other names: SC-51296SC51296SC 51296

Targets

HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on SC-51296.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SC-51296.

Explore the full profile